Opus Genetics (IRD) Total Current Liabilities (2018 - 2026)

Opus Genetics (IRD) has reported Total Current Liabilities for 9 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 61.49% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $9.3 million (down 61.49% YoY), while the FY2025 annual figure was $7.8 million, down 31.11% from the prior year.
• Total Current Liabilities grew to $9.3 million in Q1 2026 per IRD's latest filing, from $7.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $29.1 million in Q3 2025 and bottomed at $2.7 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $8.7 million across 5 years, with a median of $5.8 million in 2023.
• Annual changes were most pronounced in 2025 — Total Current Liabilities surged 380.99% — and 2026, when it tumbled 61.49%.
• Opus Genetics' Total Current Liabilities stood at $2.8 million in 2022, then soared by 46.82% to $4.0 million in 2023, then soared by 179.44% to $11.3 million in 2024, then tumbled by 31.11% to $7.8 million in 2025, then grew by 20.04% to $9.3 million in 2026.
• Business Quant data shows IRD's Total Current Liabilities at $9.3 million in Q1 2026, $7.8 million in Q4 2025, and $29.1 million in Q3 2025.